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More than a century after its description, Staphylococcus aureus
is still a dangerous pathogen for humans. Despite constant
improvement in patient care, S. aureus infections remain
associated with considerable morbidity and mortality, both in
hospitals and in the community [1]. The clinical and molecular
epidemiology of S. aureus infections has changed dramatically
over the past two decades, with the emergence of commu-
nity-associated methicillin-resistant S. aureus (CA-MRSA).
These changes have been quickly identiﬁed, thanks to the
unusual combination in CA-MRSA of methicillin resistance and
low rates of resistance to non-b-lactam antimicrobials. Inter-
estingly, these clones have emerged and spread in patients who
lack the classic epidemiological risk factors for methicil-
lin-resistant S. aureus (MRSA) infection, such as healthcare
contact, suggesting that CA-MRSA epidemics could originate
from unexpected areas and populations. This worrying obser-
vation has highlighted the renewed importance of epidemio-
logical surveys of S. aureus infections and of the molecular
characterization of S. aureus strains. Such surveillance has been
extensively conducted in North America and Europe, leading
to the identiﬁcation of novel CA-MRSA clones and, more
recently, of livestock-associated MRSA [2]. However, North
America and Europe account for less than one-third of the
world’s population, and little is known about the epidemiology
of S. aureus outside of these areas. Because of the increasing
population movements worldwide, there is an urgent need to
improve our understanding of S. aureus epidemiology in
non-western parts of the world. In an attempt to bridge this
information gap, this Special Issue aimed to collect and review
the available epidemiological data in Africa, Asia, the Middle
East and Oceania, to sketch an integrated view of S. aureus
carriage and infection dynamics in terms of prevalence,
antimicrobial resistance, and molecular characteristics.
With respect to the African continent, the paper by
Schaumburg et al. [3] identiﬁed several distinctive traits of
S. aureus epidemiology, both in developed urban populations
and in remote rural communities. By far the most striking
feature of this epidemiology is the very high prevalence,
ranging from 17% to 74%, of the genes encoding the potent
leukotoxin Panton–Valentine leukocidin (PVL) in S. aureus
isolates. Most of these PVL-positive isolates are methicil-
lin-susceptible, which makes PVL epidemiology in Africa
different from that in both Europe, where the prevalence of
PVL-positive S. aureus is <2%, and North America, where the
prevalence is very high but is mostly attributable to the
exceptional diffusion of a single CA-MRSA clone. The high
prevalence of PVL-positive S. aureus in sub-Saharan Africa, the
antimicrobial multisusceptibility of the corresponding strains
and the genetic diversity of the PVL-positive lineages strongly
suggest that this geographical area could act as a reservoir for
the emergence of PVL-positive clones. Moreover, the
now-established PVL endemicity in Africa largely explains
why PVL-related infections have been frequently described in
western patients travelling to the continent.
S. aureus epidemiology in the Middle East was reviewed by
Tokajian [4]. A noteworthy observation is the recent emer-
gence of MRSA as a prevalent pathogen in several Middle East
countries, both in infection and in carriage. For example,
MRSA accounts for 45% of S. aureus nasal carriage isolates
both in children and in adult patients living in the Gaza strip.
Interestingly, most of these CA-MRSA isolates belong to
sequence type (ST)22 and are PVL-negative, in contrast to the
canonical CA-MRSA lineages described in western countries.
However, in other Middle East countries, such as Jordan and
Egypt, the CA-MRSA epidemic is mainly related to the spread
of the ST80 PVL-positive clone that had previously (and now
questionably) been termed the European clone.
As reviewed by Chen and Huang [5], the dynamics of MRSA
in Asian countries have followed, to some extent, those
observed in western countries, including the emergence of
CA-MRSA, which now accounts for >50% of S. aureus isolates
in some regions. Regarding antimicrobial resistance issues, it is
also interesting to note that glycopeptide-intermediate
S. aureus strains, which had been understandably designated
as a potential short-term major threat upon their ﬁrst
description in Japan in 1996, have never disseminated widely
in the Asian area, and have been only sporadically reported.
However, this threat could emerge again in the future in the
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form of vancomycin-resistant S. aureus strains with MICs of
>16 mg/L: such strains, which often harbour the transferrable
vancomycin resistance-encoding gene vanA, have been increas-
ingly reported from northern India and West Bengal, both in
clinical and in colonization isolates.
Oceania can be considered the cradle of CA-MRSA, was
were ﬁrst reported in remote indigenous communities from
Australia in the early 1990s. In their review, Williamson et al.
[6] investigate the considerable changes in S. aureus epidemi-
ology in this area over the past two decades. Distinct
CA-MRSA clones have emerged and spread, including ST93
and clonal complex 75 in Australia, and ST30 and ST5 in New
Zealand. This dissemination was accompanied by a signiﬁcant
increase in the burden of staphylococcal disease from 2000 to
2011, a burden that disproportionately involved indigenous
communities, especially children. A particularly striking fact in
this context is that Aboriginal children from Western Australia
are 12 times more likely to be hospitalized with staphylococcal
skin infections than other children from the same area.
Although socio-economic aspects could partly account for this
difference, it is very likely that other undiscovered risk factors
are involved in the patent preference of S. aureus for
indigenous Oceanian patients.
Overall, the landscape of S. aureus infections has evolved
worldwide at a fast pace since the turn of the millenium.
However, most of these changes had gone largely undetected
until recently in non-western countries, probably because
research efforts have been mainly focused on the catastrophic
rise of CA-MRSA in North America and on the threat of a
similar epidemic in Europe. In the increasingly connected
world of the years to come, a global view of S. aureus dynamics
will probably be necessary to comprehend and anticipate the
potentially rapid dissemination of newly emerged clones.
Surveillance efforts should be sustained, and more resources
have to be committed to investigating and controlling S. aureus
infections in areas such as Africa, India, and the Far East.
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